m+Medelevator.RU
← Поиск публикаций
Current medicinal chemistry · 2026

Role of N-Glycolylneuraminic Acid and N-Acetylneuraminic Acid Glycans in Cancer Diagnosis and Therapeutic Strategies.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Bhattacharya Sankha, Gupta Khushi, Sharma Mayank, Mukherjee Dhrubojyoti, Prajapati Bhupendra

Аннотация

This review examines the function of N-glycolylneuraminic acid (Neu5Gc) and N-acetylneuraminic acid (Neu5Ac) glycans in cancer diagnosis and treatment, specifically in their interaction with biodegradable polymeric nanoparticles. Glycans play a central role in cellular communication, immune response, and adhesion, with structural changes usually indicative of precancerous conditions, thus making them key to diagnostic and therapeutic innovations. Neu5Gc, a dietary non-human sialic acid found in red meat and other foods, becomes a part of cell membranes, evoking immune reactions through anti-Neu5Gc antibodies that promote chronic inflammation, tumour formation, and metastasis. In contrast, Neu5Ac is compatible with human physiology and holds promise in antiviral and genetic disease therapies. This review explores the uses of biodegradable polymeric nanoparticles, including those from natural polymers such as chitosan and alginate, in Neu5Gc targeting for cancer diagnosis, immunotherapy, and drug delivery. It emphasizes their biocompatibility, controlled release, and improved targeting of Neu5Gc-containing tumour antigens. The review also addresses developments in electrochemical biosensors for Neu5Gc detection and computational glycan modeling, highlighting their potential in personalized oncology. By emphasizing biodegradable polymer-based approaches, this research highlights their promise as novel agents for cancer treatment, necessitating continued investigation into glycan-polymer interactions to further improve therapeutic outcomes.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты